Magnus Medical, a medical device company and developer of brain stimulation technology for treatment of neuropsychiatric disorders, has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for the SAINT Neuromodulation System for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement from prior antidepressant medications in the current episode.
Brett Wingeier, Ph.D., co-founder and CEO of Magnus, said: “We are now at the forefront of an enormous improvement in the care of treatment-resistant depression, thanks to the work of the Magnus team and all those whose efforts have led to the SAINT technology. To read the full article, please visit: www.med-technews.com
Posted by:
Cure Talent